Regeneron Pharmaceuticals, Inc. (VIE:REGN)
Austria flag Austria · Delayed Price · Currency is EUR
651.60
-11.80 (-1.78%)
At close: Mar 6, 2026

Regeneron Pharmaceuticals Ratios and Metrics

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Market Cap
67,23170,19767,17382,67168,03659,050
Market Cap Growth
-5.38%4.50%-18.75%21.51%15.22%33.09%
Enterprise Value
53,52865,12161,74575,66663,69955,854
PE Ratio
17.5218.6118.5825.2618.888.77
Forward PE
15.7417.1115.1919.3617.2911.00
PEG Ratio
-2.930.954.75--
PS Ratio
5.505.695.507.336.504.27
PB Ratio
2.532.612.663.703.493.66
P/TBV Ratio
2.262.682.793.853.613.78
P/FCF Ratio
19.3519.9921.3024.7917.8710.51
P/OCF Ratio
15.8516.3917.6620.9215.779.69
EV/Sales Ratio
4.335.285.056.706.084.04
EV/EBITDA Ratio
14.5018.3616.0419.6814.577.03
EV/EBIT Ratio
16.7721.1517.9821.7315.627.26
EV/FCF Ratio
15.4018.5519.5822.6916.739.94
Debt / Equity Ratio
0.090.090.090.100.120.11
Debt / EBITDA Ratio
0.660.660.610.610.530.29
Debt / FCF Ratio
0.660.660.740.700.610.41
Net Debt / Equity Ratio
-0.19-0.19-0.21-0.31-0.22-0.16
Net Debt / EBITDA Ratio
-1.43-1.43-1.41-1.82-0.99-0.32
Net Debt / FCF Ratio
-1.45-1.45-1.72-2.10-1.14-0.46
Asset Turnover
0.370.370.400.420.450.75
Inventory Turnover
0.670.670.700.730.721.26
Quick Ratio
3.283.283.864.824.162.98
Current Ratio
4.134.134.735.695.063.56
Return on Equity (ROE)
14.87%14.87%15.95%16.26%20.94%54.21%
Return on Assets (ROA)
7.87%7.87%10.40%12.23%15.49%36.37%
Return on Invested Capital (ROIC)
11.50%11.50%16.48%20.01%23.65%54.51%
Return on Capital Employed (ROCE)
10.22%10.22%12.57%14.52%19.92%49.75%
Earnings Yield
5.71%5.37%5.38%3.96%5.30%11.40%
FCF Yield
5.17%5.00%4.69%4.03%5.60%9.51%
Dividend Yield
0.47%0.46%0.00%0.00%0.00%0.00%
Payout Ratio
8.22%8.22%0.00%0.00%0.00%0.00%
Buyback Yield / Dilution
4.09%4.09%2.78%1.86%1.28%1.47%
Total Shareholder Return
4.56%4.55%2.78%1.86%1.28%1.47%
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.